In this episode of LATAM MedTech Insights, we demystify the process of registering a low-risk (Class I) medical device in Mexico. Don't let the "low-risk" classification fool you; navigating the requirements of COFEPRIS, Mexico's health authority, is a complex journey filled with potential pitfalls that can delay your market entry indefinitely. We break down the essential steps, from appointing a legally required Mexico Registration Holder (MRH) to compiling a flawless technical dossier. We uncover the most common mistakes foreign manufacturers make, such as improper document legalization and translation errors, which lead to costly rejections and wasted time. This episode is a must-listen for any MedTech company looking to tap into the lucrative Mexican market efficiently and successfully. **Case Study Highlight:** Imagine a US-based scaleup with an innovative Class I diagnostic tool. They've secured a major distributor in Mexico City, but their launch is stalled for over eight months. Why? Their technical dossier, perfectly valid for the FDA, was rejected twice by COFEPRIS due to improper Spanish translations and missing apostilles on their legal documents. This failure cost them crucial first-mover advantage and strained vital partner relations, a scenario that is all too common and entirely avoidable. **Key Questions Answered (本期干货):** * Why is a 'low-risk' classification from COFEPRIS not the same as a 'no-paperwork' registration? * What is the single most critical role of a Mexico Registration Holder, and how can choosing the wrong one jeopardize your business? * What is an apostille, and why could its absence on your documents lead to an instant rejection from COFEPRIS? * Are standard translation services sufficient for your technical dossier, or do you need a specific type of translator to be successful? * Can you really leverage your FDA 510(k) to speed up COFEPRIS approval, and what are the hidden catches? * What specific document in your dossier is most often submitted incorrectly by foreign companies? * How does the COFEPRIS Equivalency Agreement actually work, and is your device eligible? At Pure Global, we transform these complex regulatory challenges into clear market access strategies. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative in over 30 markets, including Mexico. Our blend of local expertise and advanced AI tools streamlines the registration process, saving you time and money. Stop letting regulatory hurdles block your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to get started.